Taheri Yasaman, Joković Nataša, Vitorović Jelena, Grundmann Oliver, Maroyi Alfred, Calina Daniela
Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Front Pharmacol. 2021 Jan 14;11:578823. doi: 10.3389/fphar.2020.578823. eCollection 2020.
Infection is a disease that can occur due to the entrance of a virus, bacteria, and other infectious agents. Cefiderocol is innovative cephalosporin drug that belongs to a special class of antibiotics, sideromycins, which are taken up by bacterial cells through active transport. The unique cell entry and stability to β-lactamases allow cefiderocol to overcome the most common resistance mechanisms in Gram-negative bacteria. This article aims to highlight the therapeutic efficacy, safety and tolerability of cefiderocol, with a focus on the FDA label. The pharmacological properties of cefiderocol are also summarized. In this review, we conducted literature research on the PubMed database using the following keywords: "antimicrobial treatment", "new antibiotic", "cefiderocol", "siderophore cephalosporin"; "multidrug-resistant", "Gram-negative bacilli", "critically ill patients"; "severe bacterial infections". There were identified the most relevant data about the pathophysiology of serious bacterial infections, antibacterial mechanism of action, microbiology, mechanisms of resistance, pharmacokinetic and pharmacodynamic properties of cefiderocol. The results highlighted there appeared to be clinical benefit from cefiderocol in the treatment of infections caused by Gram-negative aerobic microorganisms in adult patients with severe infections and limited treatment options.
感染是一种可能由于病毒、细菌及其他感染因子侵入而发生的疾病。头孢地尔是一种创新型头孢菌素药物，属于一类特殊的抗生素——铁载体霉素，这类抗生素通过主动转运被细菌细胞摄取。独特的细胞摄取方式和对β-内酰胺酶的稳定性使头孢地尔能够克服革兰氏阴性菌中最常见的耐药机制。本文旨在强调头孢地尔的治疗效果、安全性和耐受性，重点关注美国食品药品监督管理局（FDA）的标签内容。同时也总结了头孢地尔的药理学特性。在本综述中，我们使用以下关键词在PubMed数据库中进行了文献研究：“抗菌治疗”“新型抗生素”“头孢地尔”“铁载体头孢菌素”；“多重耐药”“革兰氏阴性杆菌”“重症患者”；“严重细菌感染”。确定了关于严重细菌感染的病理生理学、抗菌作用机制、微生物学、耐药机制、头孢地尔的药代动力学和药效学特性的最相关数据。结果表明，对于严重感染且治疗选择有限的成年患者，头孢地尔在治疗由革兰氏阴性需氧微生物引起的感染方面似乎具有临床益处。
